Sensus Healthcare Inc (NASDAQ:SRTS) has been given an average recommendation of “Hold” by the nine brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $8.30.
SRTS has been the subject of several recent research reports. B. Riley downgraded Sensus Healthcare from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $14.00 to $5.50 in a research note on Thursday, November 7th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Sensus Healthcare in a research note on Thursday, November 7th. TheStreet raised Sensus Healthcare from a “d+” rating to a “c-” rating in a research note on Monday, August 26th. Maxim Group set a $11.00 price objective on Sensus Healthcare and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, ValuEngine downgraded Sensus Healthcare from a “buy” rating to a “hold” rating in a research note on Thursday, October 17th.
A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Heartland Advisors Inc. raised its stake in Sensus Healthcare by 150.0% in the 2nd quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock valued at $2,078,000 after purchasing an additional 225,000 shares during the last quarter. BlackRock Inc. increased its stake in shares of Sensus Healthcare by 40.7% in the 2nd quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock worth $574,000 after acquiring an additional 29,990 shares during the last quarter. Essex Investment Management Co. LLC acquired a new stake in shares of Sensus Healthcare in the 3rd quarter worth $540,000. Susquehanna International Group LLP increased its stake in shares of Sensus Healthcare by 69.9% in the 2nd quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after acquiring an additional 11,311 shares during the last quarter. Finally, Wells Fargo & Company MN acquired a new stake in shares of Sensus Healthcare in the 2nd quarter worth $30,000. 9.76% of the stock is owned by hedge funds and other institutional investors.
Shares of SRTS stock traded up $0.06 during trading hours on Wednesday, hitting $3.60. 76,600 shares of the company’s stock were exchanged, compared to its average volume of 33,619. The firm has a market cap of $58.40 million, a P/E ratio of -25.71 and a beta of -0.41. The firm has a 50 day moving average of $5.09 and a two-hundred day moving average of $5.55. Sensus Healthcare has a fifty-two week low of $3.45 and a fifty-two week high of $9.23.
Sensus Healthcare (NASDAQ:SRTS) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. Sensus Healthcare had a negative return on equity of 9.78% and a negative net margin of 9.83%. The firm had revenue of $5.84 million during the quarter, compared to the consensus estimate of $7.77 million. On average, equities analysts predict that Sensus Healthcare will post -0.16 earnings per share for the current year.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Further Reading: What is the Fibonacci sequence?